Autres langues Scholar Rock Holding Corporation

Actions

SRRK

US80706P1030

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 10/09/2026			Varia. 5j.	Varia. 1 janv.
55,67 ^USD	+1,92%		-0,48%	+26,38%

10/09	Transcript : Scholar Rock Holding Corporation Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 09:20 AM
02/09	Scholar Rock reçoit la désignation Fast Track de la FDA pour son programme sur l'apitegromab dans la dystrophie musculaire facio-scapulo-humérale alors que le dosage des participants débute dans l'essai de Phase 2 FORGE	CI

Autres langues

02/09	Scholar Rock Receives FDA Fast Track Designation For Apitegromab Facioscapulohumeral Muscular Dystrophy Program As Participant Dosing Commences In Phase 2 FORGE Trial
02/09	Scholar Rock Gets FDA Fast Track, Orphan Drug Designations for Muscular Disorder Drug
02/09	Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
27/08	Scholar Rock to Present at Upcoming Investor Conferences
21/08	Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says
21/08	Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission
21/08	Scholar Rock Announces Removal Of Catalent Indiana As Fill-Finish Facility And Progresses Apitegromab Regulatory Filings With FDA, EMA, And PMDA
21/08	Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
21/08	Scholar Rock Removes Catalent Indiana From Apitegromab BLA as Fill-Finish Facility
21/08	Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
14/08	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/08	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date
07/08	Scholar Rock drops Novo Nordisk facility from marketing application for muscle weakness drug
07/08	Scholar Rock Holdings Pulls Novo Nordisk Facility From Drug Application After FDA Flag
07/08	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date
07/08	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
07/08	Scholar Rock Holdings Pulls Novo Nordisk Facility From Drug Application After FDA Flag -- Update
06/08	Scholar Rock Holding Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Scholar Rock Q2 Net Loss Narrows
06/08	Scholar Rock Reports Apitegromab Biologics License Application Progress, Initiates Phase 2 Forge Study, and Provides Updates on Srk-439 and Opal Trials
06/08	Earnings Flash (SRRK) Scholar Rock Posts Q2 Loss of $0.84 a Share, vs. FactSet Est of $0.84 Loss
06/08	Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
29/07	Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
20/07	Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026
20/07	Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)